Prosecution Insights
Last updated: April 19, 2026
Application No. 17/838,891

SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY

Final Rejection §102
Filed
Jun 13, 2022
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Trustees Of Tufts College
OA Round
4 (Final)
85%
Grant Probability
Favorable
5-6
OA Rounds
1y 11m
To Grant
80%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allow Rate
1317 granted / 1549 resolved
+25.0% vs TC avg
Minimal -5% lift
Without
With
+-4.8%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
47 currently pending
Career history
1596
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
43.6%
+3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1549 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 102 Rejections Withdrawn The rejection of claims 50-55, 57-59, 62 and 63 under 35 USC 102(a)(1), outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment narrows the scope of claimed subject matter such that it no longer reads on the cited art. Markush Search Inventor having overcome the outstanding art rejection, the search was expanded as called for under Markush examination practice, a compound-by-compound search, to include a single additional species. That species is defined when, using formula I: Y is Ph(CH2)2-; W is NR20 where R20=H; and RLipid is the diagramed structure of RLipid where p=1; R1=R2=R3=R4=H; Z=X=Y= -CH2-; m=n=1; t=0; and q=1. All other claimed but as yet unexamined subject matter is hereby withdrawn from consideration, for purposes of this Office Action, as being drawn to non-elected subject matter. This subject matter will be rejoined as appropriate as the Markush examination progresses. Claim Rejections - 35 USC § 102, NEW In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 50, 52-54, 57-59 and 63, in so far as they read on the species defined above, are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by Journal of Applied Polymer Science (2015), DOI: 10.1002/APP.42569 (10 pages). The reference explicitly teaches inventor’s compound in a reaction scheme (page 2 of 10, Scheme 1, 2nd diagramed compound in top row of scheme). The examiner again notes that the limitation of independent claim 50 “A lipidoid composition comprising a plurality of compounds…” does not distinguish over the cited art simply because it describes a characteristic of the instant Markush set of compounds which are already explicitly defined by instant formula I (i.e. a lipidoid is a substance that resembles or has the characteristics of a lipid). Furthermore, the term “plurality” simply means plural (i.e. more than one). Note that during patent examination, the pending claims must be given their broadest reasonable interpretation consistent with the specification. (See MPEP 2111.) That being the case, the fact that the independent claim includes an adjective describing the already defined Markush set of compounds of instant formula I, and that prior art reaction scheme 1 is a synthetic scheme which will intrinsically include more than a single, individual molecule of the diagramed compound (i.e. it will include a plurality of them), the prior art reaction mixture composition clearly anticipates the instant claims. Claim Objections Withdrawn The objection to claims 65 and 67-72 is withdrawn and reformulated below. Allowable Subject Matter The elected species previously being deemed free of the prior art, any claim or portion of a claim, drawn exclusively to this species constitutes allowable subject matter. Thus, claims 51, 55, 62, 65 and 67-72 are objected to because they are drawn to subject matter which encompasses allowable subject matter (the elected species) as well as subject matter which has not yet been completely searched. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 1/31/2026
Read full office action

Prosecution Timeline

Jun 13, 2022
Application Filed
Mar 22, 2024
Response after Non-Final Action
Sep 25, 2024
Non-Final Rejection — §102
Dec 20, 2024
Response Filed
Mar 18, 2025
Final Rejection — §102
May 20, 2025
Response after Non-Final Action
Jun 27, 2025
Request for Continued Examination
Jul 01, 2025
Response after Non-Final Action
Sep 07, 2025
Non-Final Rejection — §102
Dec 11, 2025
Response Filed
Jan 31, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594226
COMPOSITION FOR AMELIORATING SKIN CONDITION
2y 5m to grant Granted Apr 07, 2026
Patent 12594257
MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS
2y 5m to grant Granted Apr 07, 2026
Patent 12594242
LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595280
PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
2y 5m to grant Granted Apr 07, 2026
Patent 12576107
METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
85%
Grant Probability
80%
With Interview (-4.8%)
1y 11m
Median Time to Grant
High
PTA Risk
Based on 1549 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month